{
  "created_at": "Mon May 17 5:35:8 +0000 2021",
  "id_str": "1394145866508914690",
  "full_text": "Intellectual-property rights on covid-19 vaccines are far from the most pressing, or most restrictive, constraint https://t.co/vyxXphMC3y",
  "display_text_range": [
    0,
    137
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/vyxXphMC3y",
        "expanded_url": "https://econ.st/3obQNWb",
        "display_url": "econ.st/3obQNWb",
        "indices": [
          114,
          137
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 29,
  "favorite_count": 99,
  "possibly_sensitive": false,
  "original_created_at": "Mon May 17 04:20:51 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "covid-19ワクチンの知的財産権は、最も差し迫った、あるいは最も制限された制約ではありません。https://t.co/vyxXphMC3y"
    },
    {
      "locale": "zh",
      "full_text": "关于covid-19疫苗的知识产权远不是最紧迫或最有限制性的制约因素https://t.co/vyxXphMC3y。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "關於covid-19疫苗的知識產權遠不是最緊迫或最有限制性的制約因素https://t.co/vyxXphMC3y。"
    }
  ]
}